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g.2013.0Abstract Phenylketonuria (PKU) is an autosomal recessive metabolic genetic disorder character-
ized by a mutation in the gene for the hepatic enzyme phenylalanine hydroxylase (PAH). The dis-
ease may present clinically with seizures, albinism (excessively fair hair and skin), and a ‘‘musty
odor’’ to the baby’s sweat and urine. In the untreated classic case, mental retardation is severe, pre-
cluding speech and toilet training. Seizures are common in the more severely retarded, usually start
before 18 months of age. This study aimed to identify clinical proﬁle and impacts of newly diag-
nosed (untreated) PKU on children. Children presented to the Pediatric Department, or Pediatric
Neurology Clinic, Sohag University Hospital in whom the diagnosis of Pheylketonuria was estab-
lished based on measuring phenylalanine level in blood samples were eligible for this study. All
studied patients were subjected to thorough history, full examination, and developmental assess-
ment. Electroencephalography (EEG), computed tomography of the brain (CT), phoniatric and
audiologic evaluations were also done. During the period of the study we diagnosed 24 cases with
phenylketonuria, the main clinical presentations were global developmental delay, hyperactive
symptoms, seizures, and autistic features. CT of the brain showed that 58.3% of cases had atrophic
changes. EEG showed that 58.3% of cases had abnormal ﬁndings as generalized epileptic dis-
charges, focal epileptic discharges, and hypsarrhythmia. We concluded that untreated phenylketon-
uria still represents a signiﬁcant burden on children development and mental function in Upper
Egypt. So we recommend establishment of national screening programs and pushing it forward
as well as immediate development of speciﬁc metabolic centers in various universities and research
institutes.
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3.0011. Introduction
Phenylketonuria (PKU) is an autosomal recessive metabolic
genetic disorder characterized by a mutation in the gene for
the hepatic enzyme phenylalanine hydroxylase (PAH), render-
ing it nonfunctional [1]. This enzyme is necessary to metabolize
the amino acid phenylalanine (Phe) to the amino acid tyrosine.in Shams University.
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is converted into phenylpyruvate (also known as phenylke-
tone), which is detected in the urine [2]. The mean incidence
of PKU varies widely in different human populations. In Tur-
key, 1 in 2600 births (the highest rate in the world); in Ireland,
1 in 4500 [3], in Norway 1 in 13,000, and fewer than one in
100,000 in Finland. In the United States, about 1 in 15,000
births show classical PKU. The incidence is relatively high in
Italy, China, and Yemen [4–6]. PKU is commonly included
in the newborn screening panel of most countries, with varied
detection techniques. Most babies in developed countries are
screened for PKU soon after birth [7]. However in Egypt
screening practice for PKU does not include all neonates but
sporadic studies were done. Screening for phenylketonuria
among Egyptian newborns in Menouﬁya governorate was con-
ducted and revealed a prevalence of 1/3000 [8].
If a child is not screened during the routine newborn screen-
ing test, the disease may present clinically with seizures, albi-
nism (excessively fair hair and skin), and a ‘‘musty odor’’ to
the baby’s sweat and urine (due to phenylacetate, one of the
ketones produced). Untreated children are normal at birth.
In untreated infants, vomiting which at times projectile and
irritability are frequent during the ﬁrst 2 months of life. By
4–9 months, delayed intellectual development becomes appar-
ent [9]. In the untreated classic case, mental retardation is se-
vere, precluding speech and toilet training. Seizures, common
in the more severely retarded, usually start before 18 months
of age. During infancy, they often take the form of infantile
spasms, later changing into tonic–clonic attacks. The untreated
phenylketonuric child is blond and blue-eyed, with normal and
often pleasant features. The skin is rough and dry, sometimes
with eczema. Signiﬁcant neurologic abnormalities are rare,
although hyperactivity and autistic features are not unusual.
Microcephaly may be present as well as a mild increase in mus-
cle tone, particularly in the lower extremities. A ﬁne, irregular
tremor of the outstretched hands is seen in approximately 30%
of the patients. Parkinsonian-like extrapyramidal symptoms
also have been encountered. The plantar response is often
extensor [10].
A variety of electroencephalographic (EEG) abnormalities
have been found, but hypsarrhythmic patterns, recorded even
in the absence of seizures, and single and multiple foci of spike
and polyspike discharges are the most common [11]. MRI of
the brain is abnormal in almost every patient, regardless of
when treatment was initiated [12]. As PKU is the leading cause
for severe morbidity and mental retardation although a pre-
ventable disease and to the best of our knowledge, there are
few studies done on PKU in Upper Egypt, this research aimed
to identify clinical proﬁle and impacts of newly diagnosed (un-
treated) PKU on children in Sohag University Hospital.
2. Patients and methods
2.1. Study design
This is a single center observational Cohort Study, done in
Pediatric Department, and Pediatric Neurology Clinic at So-
hag University Hospital, Upper Egypt, during the period from
January 2009 through June 2012. All infants and children clin-
ically suspicious of having PKU during the study period were
included. The diagnosis of PKU was established based on clin-ical manifestations and laboratory conﬁrmation by measuring
phenylalanine level in the blood sample. Consent was taken
from the family to conduct this research and approved by
the Faculty of Medicine, Sohag University Ethics Committee.
2.2. Methods
Phenylalanine assay in blood was done by using the Bio-Rad
Laboratories products, Microplate Neonatal PHE/GAL(gal-
actose)–Assay-(Test Kit 532-6053); for quantitative microplate
assay of phenylalanine and galactose in the newborn blood to
screen for phenylketonuria, galactosemia on Whatman 903 pa-
per and level P3 mg/dl was considered elevated. All studied
patients were subjected to thorough clinical history including
detailed history of the presenting symptoms like seizures and
developmental history. Autistic symptoms, hyperactivity
symptoms, and family history of similar condition, presence
of epilepsy, mental retardation or global developmental delay
were also clariﬁed.
Full clinical examination (general, systematic, and detailed
neurological examinations), and developmental assessment
were done. Computed tomography of the brain (CT) and elec-
troencephalography (EEG) were done for all patients. All pa-
tients were referred to the Phoniatric Unit and were subjected
to Ear, Nose, and Throat (ENT) examination, language eval-
uation as well as assessment of passive and active vocabulary
were done. Also evaluation of the autistic features using the
American Psychiatric Association diagnostic criteria for aut-
ism [13] and Childhood Autism Rating Scale (CARS) was
done; the degree of autistic disorders was set 30 serving as a
cut off for the diagnosis of autism, mild-moderate autism
(30–37) and severe autism (>37) [14]. Psychometric evaluation
was done using Vineland adaptive Behavior Scales [15] and
Stanford–Binet Intelligence Scales [16]. Complete audiological
evaluation was done in the Audiologic Unit.3. Results
3.1. Descriptive data of the studied patients
This study was done on newly diagnosed cases of PKU and
they did not receive any treatment or dietary management be-
fore. The cornerstone for diagnosis of our cases was measuring
the blood phenylalanine level. The mean phenylalanine level in
the studied cases was 15.80 ± 8.84 mg/dl, range 3.8–28.1. The
total number of patients conﬁrmed to have pheylketonuria
(PKU) was 24 cases, ﬁfteen of them (62.5%) were boys and nine
(37.5%) were girls. Twelve cases (50%) had classic PKU (Phe
level >20 mg/dl), seven cases (29.2%) had mild PKU (Phe level
10–20 mg/dl), and ﬁve cases (20.8%) had mild hyperphenylala-
ninemia (MHP) (Phe level <10 mg/dl) The age of presentation
ranged from 0.08 to 11 years with mean age of presentation of
3.37 ± 3 years while the median age was 2.8 years.
3.2. Clinical features
Clinical features of the studied cases showed that the majority
16 of 24 cases (66.7%) had global developmental delay (affec-
tion of more than two developmental domains; motor, lan-
guage, and social development), while 11 cases had
Figure 1 A 5.5 month old girl presented by motor delay, blond
features, and microcephaly.
Figure 2 A 5.5 year old girl with global developmental delay and
blond features.
Figure 3 An 11 year old boy presented by delayed language
development in addition to other autistic and blond features.
Figure 4 An 18 month old boy with global developmental delay,
hyperactivity and blond features.
Figure 5 Chart showing types of seizures reported in the cases.
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and included four cases with generalized tonic–clonic seizures,
three cases with infantile spasms, and two cases with febrile sei-
zures, and eight cases had autistic features. Isolated language
delay without autistic features was found in two cases, moder-
ate hearing loss was reported in two cases, microcephaly in
three cases, while one case had delayed motor milestones,
and one case had dysmorphic features (Figs. 1–5), (Table 1).
3.3. CT of the brain
CT study of the brain showed that 14 cases (58.3%) had brain
atrophic changes, seven cases (29.2%) had normal imaging,
two cases (8.3%) had white matter disease with brain atrophy
while one case (4.2%) had brain atrophy with lissencephaly
(Fig. 6), (Table 2).
3.4. EEG ﬁndings
EEG was done in all cases and showed that 10 cases (42.7%)
had normal EEG ﬁnding, six cases had generalized epileptic
discharges, ﬁve cases had focal epileptic discharges, and three
cases had hypsarrhythmia pattern (Table 3).
Table 1 Clinical features of the included cases.
Clinical features Number
of cases
Percentages from
total number
(24) (%)
Global developmental delay 16 66.7
Hyperactivity symptoms 11 45.8
Seizures 9 37.5
Autistic features 8 33.3
Microcephaly 3 12.5
Isolated delayed language development 2 8.3
Hearing impairment 2 8.3
Dealyed motor development 1 4.2
Dysmorphic facial features 1 4.2
(It is to be noted that one case may have more than one
presentation).
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In our study we prospectively diagnosed 24 cases with phenyl-
ketonuria. The disease was more common in boys than girls
(62.5% versus 37.5%). The mean age of the studied patients
was 3.37 years and this correlates with the study done in Tuni-
sia by Khemir et al. [17], to evaluate the role of phenylketon-Figure 6 CT brain ﬁndings of one cauria in mental retardation. They found that, the PKU
estimated frequency was 1/7631 in mentally retarded children
with a mean age of 4 years. Our results showed that the mean
phenylalanine level was 15.8 mg/dl while in Tunisia, the phen-
ylalanine mean level was 28 mg/dl (1680 lmol/L), and in the
Egyptian study done in the Menouﬁya Governorate by El Ara-
by et al. [8], the mean phenylalanine level was 3.19 mg/dl. Our
results regarding mean age were lower than those of Karim-
zadeh et al. [18], as they evaluated 105 patients with the diag-
nosis of PKU and the mean age of the patients was
8.5 ± 6.2 years.
In our series, 50% of cases had classic PKU and the dom-
inant clinical manifestations were global developmental delay,
hyperactivity symptoms, autistic features, and seizures while in
the Tunisian study [17], the classical PKU form accounted for
85.3% of cases and the dominant clinical symptoms were:
mental retardation (88.2%), motor delays (87.7%), speech dif-
ﬁculties (83.2%) and pigmentation anomalies (61.7%).
37.5% of our cases had seizures; the commonest seizure
type was generalized tonic–clonic. In the study done by Karim-
zadeh et al. [18], 52.3% had seizure and 47.7% were clinically
seizure-free. Also we found that abnormal EEG was more
common as detected in 52.4% of patients. Of these, generalized
epileptic discharges were the commonest. These ﬁndings agree
with the study done by Karimzadeh et al. [18], as they foundse showing diffuse brain atrophy.
Table 2 CT Brain ﬁndings of the included cases.
CT ﬁndings Number
of cases
Percentages
Normal ﬁndings 7 29.17
Abnormal Findings 17 70.83
Brain atrophic changes 14 82.35
White matter disease with brain atrophy 2 11.76
Brain atrophy with lissencephaly 1 5.88
Table 3 EEG ﬁndings of the included cases.
EEG ﬁndings Number
of cases
Percentages (%)
Normal 10 41.7
Abnormal 14 58.3
Generalized epileptic discharge 6 42.86
Focal epileptic discharge 5 35.71
Hypsarrhythmia 3 21.43
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of the patients had an abnormal EEG and nearly 30% had a
normal EEG in the beginning which became abnormal later
as stated by Gross et al. [11]. In an Egyptian study done by Ab-
del-Salam et al. [19], 25% of the patients had seizure, but more
than 50% had an abnormal electroencephalogram, which
means some PKU patients had an abnormal EEG without
any clinical seizure. There is evidence that subclinical dis-
charges can cause psychocognitive impairment and behavioral
disturbance [18]. Karimzadeh and Tabarestani [20] reported
negative effects of this epileptic discharge on the choice reac-
tion time, verbal and nonverbal communication and behav-
ioral disorder.
Behavioral abnormalities were also studied in our series as
they represented signiﬁcant clinical presentations of PKU.
Hyperactivity manifestations were the commonest (45.8%)
while autistic features were deﬁned in 33.3%. In the study of
Karimzadeh et al. [18], the behavioral–emotional scale evalua-
tion showed that the frequency of behavioral disorder was
85.7% of cases and 42.8% in control patients. Some neuropsy-
chological damage occurs even in treated PKU as reported by
DeRoche and Welsh [21]; reaction times are delayed in PKU
and this relates to concurrent elevated phe levels. They also
said that there are other behavioral and psychiatric symptoms
attributed to PKU. Poor dietary control early in life results in
anxiety, hyperactivity and social withdrawal, and those with
satisfactory early treatment still appear to have a higher risk
of low self-esteem and possibly depression.
In our study CT of the brain showed that the majority
(70.8%) of cases had abnormal ﬁndings, mainly brain atrophic
changes and white matter disorders. These radiological ﬁnd-
ings obtained by CT were in agreement with radiological ﬁnd-
ings obtained by MRI of the brain in other studies [12,22–25].
5. Conclusion
We concluded that PKU still has adverse effects on children in
Upper Egypt leading to developmental problems, mental retar-
dation, and behavioral abnormalities. We recommend estab-
lishment of national screening programs and pushing themforward, immediate development of speciﬁc metabolic centers
in various universities and research institutes especially in
Upper Egypt.
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